Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in colorectal cancer
- New trial
Colorectal cancer
Phase 1 Trial: HistoSonics Histotripsy (ultrasound cavitation tissue ablation) in advanced colorectal metastases
Investigating whether combining histotripsy with standard palliative chemotherapy improves progression-free survival in patients with unresectable, bilobar colorectal liver metastases, this prospective, single-arm…
NCT07044362 Exploratory - New trial
Colorectal cancer
Phase II trial of fruquintinib (VEGFR inhibitor) with 5FU-based therapy in advanced colorectal cancer
Conducted at Houston Methodist Neal Cancer Center, this Phase II trial evaluates the safety and efficacy of combining 5FU-based chemotherapy (FOLFIRI or mFOLFOX6) with fruquintinib, a VEGFR inhibitor, as a first-line…
NCT07042685 Exploratory - New trial
Colorectal cancer
Phase 1 Abemaciclib (CDK4/CDK6 inhibitor) and 5-fluorouracil study in refractory colorectal cancer
This Phase 1 trial by the National Cancer Institute evaluates the safety, tolerability, and optimal dosing of abemaciclib combined with 5-fluorouracil in patients with metastatic, refractory colorectal cancer.…
NCT06654037 Exploratory - New trial
Colorectal cancer
Phase 2 trial: BMS-986340, a CCR8-targeting antibody, in advanced microsatellite-stable colorectal cancer
The study evaluates a single‐arm regimen combining BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab for patients with advanced or metastatic refractory microsatellite-stable colorectal cancer. Conducted…
NCT07011550 Exploratory - Trial result
Colorectal cancer
EGFR/MET BsAb Amivantamab Inflames Tumor, 9-mo PFS in AREG-High Refractory mCRC
Amivantamab, an EGFR–MET bispecific antibody with effector-cell engagement, was given as IV monotherapy in the Phase 1b/2 OrigAMI-1 trial (NCT05379595) to 76 heavily pre-treated, RAS/BRAF/EGFR wild-type metastatic…
NCT05379595 - New trial
Colorectal cancer
Phase 2 Trial of CBX-12, a Topoisomerase I Inhibitor, for Metastatic Colorectal Cancer
This trial evaluates CBX-12 given as a 60-minute IV infusion every 21 days in patients with chemotherapy-refractory, microsatellite stable metastatic colorectal cancer. Eligible participants include those with…
NCT06730100 - Trial result
Colorectal cancer
First-line encorafenib + cetuximab + mFOLFOX6 doubles survival to 30 mo in BRAF-V600E metastatic CRC
Encorafenib (BRAF V600E inhibitor) plus cetuximab (EGFR mAb) and mFOLFOX6 chemotherapy was tested against investigator-choice oxaliplatin-based chemotherapy ± bevacizumab in the phase 3 BREAKWATER trial…
NCT04607421 - Trial result
Colorectal cancer
DSP107 (CD47×4-1BB) + atezolizumab doubles survival and controls disease in 62% of refractory MSS colorectal cancers
DSP107 is a bi-specific fusion protein that tethers trimeric 4-1BBL to CD47 overexpressed on tumour cells, delivering conditional activation of immune response.. In a phase 2 expansion (NCT04440735), 50 heavily…
NCT04440735 - Trial result
Colorectal cancer
Retifanlimab + Carboplatin/Paclitaxel Cuts Risk of Progression 37% Across All Subgroups in Advanced Anal Cancer (POD1UM-303)
In the POD1UM-303 phase 3 trial (NCT04472429), 308 patients with inoperable locally recurrent or metastatic SCAC were randomised 1:1 to retifanlimab (PD-1 Ab) + carboplatin/paclitaxel or placebo + chemotherapy.…
NCT04472429 - New trial
Colorectal cancer
Phase 1b HRX215 MKK4 inhibitor trial for post-hepatectomy metastatic colorectal cancer
This double-blind, randomized, placebo-controlled trial assesses the safety and pharmacokinetics of HRX215 in adults following liver surgery for metastatic colorectal cancer. Eligible participants include those…
NCT06638502 - New trial
Colorectal cancer
Phase 2 Leronlimab, a CCR5-directed mAb in relapsed microsatellite stable colorectal cancer.
This open-label, randomized, multi-center study evaluates two Leronlimab doses combined with trifluridine-tipiracil plus bevacizumab in patients with CCR5-positive metastatic colorectal cancer who progressed on prior…
NCT06699836 - Trial result
Colorectal cancer
MK-1084 (KRAS G12C inhibitor) plus cetuximab drives 50% responses in advanced colorectal cancer
Phase 1 KANDLELIT-001 (NCT05067283) enrolled pre-treated KRAS G12C-mut CRC: 53 received MK-1084 monotherapy (ORR 36%), 34 got MK-1084 + cetuximab after ≥2 prior lines (ORR 50%), and 20 front-line patients received…
NCT05067283 - New trial
Colorectal cancer
Phase I Trial of CA-4948 (IRAK4/FLT3 Inhibitor) with FOLFOX and Bevacizumab in Metastatic Colorectal Cancer
The NCI is evaluating the safety and optimal dosing of CA-4948—an investigational IRAK4 and FLT3 inhibitor—in combination with FOLFOX plus bevacizumab as a first-line treatment for metastatic colorectal cancer.
NCT06696768 - New trial
Colorectal cancer
Phase II NALIRIFOX in Advanced Unresectable Small Bowel Tumors (MMRp/MSS)
This H. Lee Moffitt Cancer Center phase II outpatient study is evaluating NALIRIFOX—combining nanoliposomal irinotecan (a topoisomerase I inhibitor), oxaliplatin, 5-FU, and leucovorin—in advanced unresectable small…
NCT06835387 - New trial
Colorectal cancer
A Phase II Trial of Tiragolumab in Combination With Atezolizumab and Bevacizumab in Patients With Previously Treated, Microsatellite Stable, Metastatic Colorectal Adenocarcinoma
This trial is evaluating whether combining tiragolumab, atezolizumab, and bevacizumab can safely and effectively treat advanced MSI-stable colorectal cancer, with assessments including imaging, labs, and optional…
NCT06784947 - Trial result
Colorectal cancer
Cetuximab β Plus FOLFIRI Delivers Superior Outcomes in Chinese mCRC Patients
In this phase 3 trial of 505 RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients, adding cetuximab β to FOLFIRI as a first-line treatment significantly improved median progression-free survival (13.1 vs.…
- New trial
Colorectal cancer
Phase II Pilot Study: Y-90, Capecitabine & Atezolizumab in Unresectable CRC Liver Metastases (METEORITE)
Brown University is leading a single-arm phase II trial evaluating yttrium-90 radioembolization combined with capecitabine and atezolizumab for patients with oligometastatic colorectal cancer liver metastases…
NCT06555133 - Trial result
Colorectal cancer
EMB-01 Delivers Dual EGFR/cMET Targeting with Promising Efficacy in Heavily Pretreated mCRC
In this international phase Ib/II study, EMB-01 monotherapy at 1600 mg showed encouraging results in 48 metastatic colorectal cancer patients—particularly in left-sided, RAS/RAF wild-type mCRC—with a 24.1% partial…
- Trial result
Colorectal cancer
High miR-494 Expression Predicts Poorer Outcomes and Alters Key Gene Targets in mCRC
In the CALGB/SWOG 80405 trial, high tumor miR-494 levels were significantly associated with shorter progression‐free survival overall and in cetuximab‐treated metastatic colorectal cancer patients, while in vitro…
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.